1.2 Pre-Procedural Clinical Evaluation, Labs, Consents & The Universal Time-Out

1.2 Pre-Procedural Clinical Evaluation, Labs, Consents & The Universal Time-Out

The pre-procedural phase in the electrophysiology suite demands rigorous clinical scrutiny. Patients presenting for diagnostic electrophysiology studies, catheter ablation, or cardiac implantable electronic device (CIED) procedures frequently carry significant cardiopulmonary comorbidities, complex anticoagulation regimens, and heightened vulnerabilities to sedative complications. A systematic approach to clinical assessment, laboratory optimization, allergy prophylaxis, and team verification through the Universal Time-Out ensures patient safety and mitigates procedural morbidity.

---

Comprehensive EP Clinical Evaluation & Risk Stratification

Clinical evaluation begins with an in-depth review of the patient's cardiovascular history, structural substrate, and anesthetic vulnerability.

Cardiovascular Substrate & Functional Capacity

• Arrhythmia Phenotyping: Characterize the presenting arrhythmia: paroxysmal versus persistent atrial fibrillation (AF), typical cavotricuspid isthmus-dependent atrial flutter versus atypical scar flutter, supraventricular tachycardia (AVNRT, AVRT, focal atrial tachycardia), or wide-complex ventricular arrhythmias (premature ventricular contractions [PVCs], non-sustained or sustained monomorphic/polymorphic ventricular tachycardia [VT], ventricular fibrillation [VF] arrest survivor).
• Structural Heart Disease & Hemodynamic Status: Evaluate left ventricular ejection fraction (LVEF), regional wall motion abnormalities, left ventricular end-diastolic dimensions, and left atrial volume index (LAVI > 34 mL/m² reflects chronic atrial dilation, elevated filling pressures, and lower success rates in catheter ablation). Review prior surgical interventions: median sternotomy, coronary artery bypass grafting (CABG; saphenous vein grafts or internal mammary arteries may run in close proximity to the pericardium or atrial free wall), surgical valve replacements, or transcatheter septal occluders that alter transseptal puncture geometry.
• Functional Reserve: Document New York Heart Association (NYHA) functional class (Class I–IV). Assess exercise capacity in Metabolic Equivalents of Task (METs); a functional capacity < 4 METs (inability to climb a flight of stairs or walk up a hill without stopping) strongly correlates with perioperative cardiopulmonary complications.

Pre-Sedation Airway & Pulmonary Risk Stratification

Because many EP procedures are conducted under conscious/moderate sedation or monitored anesthesia care (MAC), identifying an anatomically difficult airway or a high risk of sleep apnea is critical for preventing acute hypoxemic crises.

• Mallampati Score: Evaluated with the patient seated upright, mouth wide open, and tongue protruded without phonating:
  • Class I: Soft palate, fauces, uvula, and anterior/posterior tonsillar pillars fully visible.
  • Class II: Soft palate, fauces, and uvula visible.
  • Class III: Soft palate and base of uvula visible.
  • Class IV: Soft palate not visible at all; only hard palate visible (predicts difficult bag-mask ventilation and endotracheal intubation).
• Thyromental Distance: Distance from the thyroid notch to the tip of the chin with the neck fully extended. A distance < 6 cm (approximately 3 fingerbreadths) indicates an acute laryngeal angle and difficult direct laryngoscopy.
• STOP-BANG Scoring for Obstructive Sleep Apnea (OSA):
  • Snoring loudly, Tired during the day, Observed apnea, high blood Pressure, BMI > 35 kg/m², Age > 50, Neck circumference > 16 inches (females) or 17 inches (males), Gender male.
  • A score of ≥ 3 indicates intermediate to high risk of upper airway collapse, prolonged apnea, and severe hypoxemia during sedation, necessitating advanced airway readiness (capnography monitoring, oral/nasopharyngeal airways, continuous positive airway pressure [CPAP] availability).

---

Fasting (NPO) Guidelines & Peri-Procedural Pharmacology

Pulmonary aspiration of gastric contents is a devastating sedation-related emergency associated with chemical pneumonitis, respiratory failure, and mortality. Strict adherence to fasting intervals and targeted medication adjustments is mandatory.

American Society of Anesthesiologists (ASA) Fasting Guidelines

• Clear Liquids: Minimum 2 hours fasting. Permitted: water, fruit juices without pulp, clear broth, black coffee, and plain tea. Non-clear liquids (milk, creamer, alcohol) are strictly prohibited.
• Breast Milk: Minimum 4 hours fasting.
• Light Meal: Minimum 6 hours fasting. Defined as plain toast and clear liquids. Meals containing butter, eggs, or light fats also require at least 6 hours.
• Heavy Meal / Fried or Fatty Foods: Minimum 8 hours fasting. Meats, deep-fried items, and high-fat foods dramatically delay gastric emptying.

Critical Chronic Medication Adjustments

• GLP-1 Receptor Agonists (e.g., Semaglutide, Tirzepatide, Dulaglutide): These incretin mimetics substantially delay gastric emptying and retain large volumes of acidic gastric fluid and undigested solid food even after 12 to 24 hours of fasting. Current ASA consensus guidelines recommend withholding daily formulations on the day of the procedure and withholding weekly formulations for 7 days prior to elective sedation or general anesthesia. If the drug was not held, the patient must be evaluated with point-of-care gastric ultrasound or treated as a full stomach requiring rapid sequence induction (RSI) with endotracheal intubation.
• SGLT2 Inhibitors (e.g., Empagliflozin, Dapagliflozin): Withhold 3 to 4 days prior to the procedure. Prolonged fasting, perioperative stress, and volume depletion dramatically elevate the risk of euglycemic Diabetic Ketoacidosis (euDKA), where severe metabolic acidosis occurs with normal or minimally elevated blood glucose levels (< 250 mg/dL).
• Renin-Angiotensin System Antagonists (ACE Inhibitors and ARBs): Withhold on the morning of the procedure unless specifically directed by the electrophysiologist. Continuing ACE inhibitors or ARBs frequently precipitates refractory "vasoplegic" hypotension upon sedation induction, unresponsive to standard phenylephrine boluses.
• Beta-Blockers and Antiarrhythmics: Typically continued with a sip of water on the morning of CIED procedures or AF ablation. However, in patients presenting for diagnostic EP studies or SVT ablation, antiarrhythmic agents (Class I and Class III) and AV nodal blocking agents are typically discontinued for at least 5 half-lives prior to the study (e.g., amiodarone requires weeks to wash out, whereas metoprolol, flecainide, or sotalol require 3–4 days) to avoid masking accessory pathways, dual AV nodal physiology, or inducible ventricular tachycardia.

---

Baseline Laboratory Stratification & Action Thresholds

Electrolyte stability, hemostatic balance, and renal clearance must be confirmed prior to vascular puncture.

Electrolyte Targets & Arrhythmogenesis

• Serum Potassium (Target: 4.0 to 5.0 mEq/L):
  • Hypokalemia (< 4.0 mEq/L): Hyperpolarizes the resting cardiac membrane potential, accelerates phase 4 diastolic depolarization, prolongs the action potential duration, and delays ventricular repolarization (manifesting on surface ECG as ST-segment depression, T-wave flattening, and prominent U-waves). Hypokalemia triggers early afterdepolarizations (EADs), non-sustained VT, and refractory ventricular fibrillation when mechanical catheter irritation occurs. Hypokalemia must be aggressively repleted prior to sheath insertion.
  • Hyperkalemia (> 5.2 mEq/L): Partially depolarizes resting membrane potential, inactives sodium channels, slows myocardial conduction velocity (QRS widening, peaked T waves), and markedly elevates pacing capture thresholds, potentially causing failure to capture during pacemaker testing or entrainment pacing.
• Serum Magnesium (Target: > 2.0 mg/dL / > 1.0 mmol/L):
  • Magnesium is an obligatory cofactor for the membrane-bound Na+/K+-ATPase pump. Hypomagnesemia impairs intracellular potassium re-uptake, destabilizes cardiac repolarization currents, and directly precipitates polymorphic ventricular tachycardia (Torsades de Pointes), particularly in the presence of antiarrhythmic drugs that prolong the QT interval (sotalol, dofetilide, ibutilide).

Coagulation Profiles & Anticoagulation Regimens

• Uninterrupted Warfarin for Left Atrial Ablation: Large randomized clinical trials have established that performing catheter ablation for atrial fibrillation on uninterrupted warfarin with an INR maintained between 2.0 and 3.0 significantly reduces the incidence of periprocedural stroke and systemic thromboembolism without increasing major bleeding or cardiac tamponade, compared to regimens involving warfarin interruption and low-molecular-weight heparin (LMWH) bridging.
• Warfarin Management for CIED Implantation: Uninterrupted warfarin (INR 2.0–3.0) is safe, whereas heparin bridging is strictly contraindicated due to a 3- to 4-fold increase in pocket hematomas. Alternatively, in low-thromboembolic-risk patients, warfarin is held 3 to 5 days pre-procedure to achieve an INR < 1.5 to 1.8 at the time of pocket creation.
• Direct Oral Anticoagulants (DOACs - Apixaban, Rivaroxaban, Dabigatran, Edoxaban):
  • For AF Ablation: Typically administered as a minimally interrupted regimen (withholding only the single morning dose on the day of the procedure) or uninterrupted therapy.
  • For CIED Implantation: Held for 24 to 48 hours prior to pocket incision, depending on the agent's renal clearance and the patient's creatinine clearance (CrCl). Dabigatran requires a 48- to 72-hour hold if CrCl < 50 mL/min.
• Platelet Count: Minimum safe threshold is > 50,000/µL for routine venous access and > 100,000/µL for arterial cannulation, transseptal access, or major device pocket creation.
• Renal Function (eGFR & Creatinine): An eGFR < 30 mL/min/1.73m² signals severe renal insufficiency, heightening the risk of contrast-induced nephropathy during fluoroscopic venography and requiring dose adjustment or avoidance of renally cleared drugs (e.g., sotalol, dofetilide, dabigatran, low-molecular-weight heparin).

---

Allergy Screening & Targeted Prophylaxis Protocols

Allergy screening must distinguish true IgE-mediated or anaphylactoid hypersensitivity from mild drug intolerances.

Iodinated Radiocontrast Allergy

• Pathophysiology: Most reactions to iodinated contrast media are non-IgE-mediated anaphylactoid reactions resulting from direct mast cell and basophil degranulation.
• Elective Oral Premedication (Greenberger 13-Hour Regimen):
  • Prednisone: 50 mg orally administered at 13 hours, 7 hours, and 1 hour prior to contrast administration.
  • Diphenhydramine: 50 mg orally or IV administered 1 hour prior to the procedure.
• Urgent / Rapid IV Premedication (Minimum 4 to 5 hours required):
  • Methylprednisolone: 40 mg IV (or Hydrocortisone 200 mg IV) administered every 4 hours for at least two doses prior to contrast exposure, plus Diphenhydramine 50 mg IV 1 hour prior. Corticosteroids require a minimum of 4 to 6 hours to alter genomic transcription and reduce mast cell mediator release; administering IV steroids 15 minutes before contrast provides zero protective effect against anaphylaxis.

Latex Allergy

• Protocol: Patients with documented type I latex allergies must be scheduled as the first case of the day to minimize aerosolized latex powder. All latex-containing gloves, tourniquets, blood pressure cuffs, and rubber vial stoppers must be removed from the suite. Latex-free catheters and stopcocks must be verified.

Heparin-Induced Thrombocytopenia (HIT Type II)

• Pathophysiology: An immune-mediated reaction where IgG antibodies bind to complexes of platelet factor 4 (PF4) and heparin, causing platelet activation, profound thrombocytopenia (typically a > 50% drop from baseline), and catastrophic arterial and venous thrombosis.
• Management: Unfractionated heparin and LMWH are absolutely contraindicated. If systemic anticoagulation is required for left-sided catheter ablation or bridging, direct thrombin inhibitors must be utilized:
  • Bivalirudin: IV bolus of 0.75 mg/kg, followed by continuous infusion of 1.75 mg/kg/hr, titrated to maintain target Activated Clotting Time (ACT 300–350 seconds).
  • Argatroban: Continuous infusion of 2 mcg/kg/min (adjusted for hepatic impairment), titrated to maintain target aPTT or ACT.

Protamine Sulfate Allergy

• High-Risk Populations: Patients with prior exposure to NPH insulin (which contains protamine to prolong absorption), patients with severe fish or seafood allergies, and males who have undergone vasectomy (who develop anti-sperm antibodies that cross-react with fish-derived protamine).
• Adverse Reactions: Manifests as acute systemic vasodilation, catastrophic non-cardiogenic pulmonary edema, and severe pulmonary hypertension with acute right ventricular failure.
• Prevention & Management: Administer a slow test dose; infuse therapeutic doses slowly (never exceed 50 mg over a 10-minute window); premedicate with H1/H2 antihistamines and corticosteroids; ensure immediate availability of vasopressors (epinephrine) and inotropic support.

---

Informed Consent Verification

Informed consent is an ethical and legal mandate confirming that the patient understands the nature of the procedure, intended clinical benefits, therapeutic alternatives, and potential hazards.

Essential Legal & Clinical Elements

• Operator Accountability: Informed consent must be obtained and documented by the operating electrophysiologist (or fellow under direct supervision) prior to the administration of any sedative premedication (midazolam, fentanyl) that would compromise decision-making capacity.
• Specific Core Procedural Risks Disclosed:
  • Pericardial Tamponade / Perforation: Risk of cardiac chamber perforation (0.5% to 1.5% in AF/VT ablation), requiring urgent pericardiocentesis or emergent sternotomy.
  • Thromboembolic Stroke / TIA: Cerebral embolization (0.2% to 0.5% in left atrial procedures).
  • Complete Atrioventricular Block: Inadvertent permanent injury to the AV node or His bundle during ablation of slow-pathway AVNRT, septal accessory pathways, or parahisian arrhythmias, necessitating lifelong permanent pacemaker implantation (~0.5% to 1.0%).
  • Major Vascular Complications: Retroperitoneal hemorrhage, femoral pseudoaneurysm, arteriovenous fistula, and massive hematoma (1% to 3%).
  • Esophageal Injury: Atrio-esophageal fistula formation following left atrial posterior wall ablation (rare < 0.1%, but carries > 50% mortality).
  • Phrenic Nerve Paralysis: Diaphragmatic hemiparalysis resulting from thermal injury during right pulmonary vein or cryoballoon ablation.
  • Death: Procedural mortality benchmarked at < 0.1% to 0.2% for elective ablation.

---

The Universal Time-Out Protocol

Mandated by The Joint Commission National Patient Safety Goals, the Universal Time-Out is an active, standardized procedural pause executed immediately before skin incision or vascular cannulation.

Multi-Disciplinary Participation & Execution

• The "Sterile Cockpit": All non-essential activities must cease. Music must be silenced, side conversations terminated, and catheter flushing paused. All team members must actively engage and verbally confirm each verification item: operating electrophysiologist, scrub specialist/RCES, circulating registered nurse, recording system specialist, and anesthesia provider.

Universal Time-Out Structured Verification Checklist

1. Patient Identity: Verified using at least two active, unique identifiers (full legal name and date of birth) cross-checked against the hospital wristband, medical chart, and signed consent form.
2. Planned Procedure & Anatomical Laterality: Clear verbal statement of the specific procedure (e.g., "Electrophysiology study, 3D electroanatomic mapping, and radiofrequency catheter ablation of typical cavotricuspid isthmus atrial flutter") and planned vascular access laterality (e.g., "Right and left femoral venous access").
3. Site Marking Verification: Required for any procedure involving laterality, distinct anatomical structures, or prepectoral CIED pocket creation (left versus right prepectoral region). The operator's physical surgical mark must be verified at the incision site.
4. Allergies & Prophylactic Antibiotics: Review of all documented allergies. For CIED implantation, confirmation that weight-adjusted intravenous prophylactic antibiotics were completely infused within 60 minutes prior to skin incision (Cefazolin 2 g IV, or 3 g if patient weight > 120 kg; or Vancomycin 15 mg/kg IV completed within 120 minutes for MRSA colonization or severe beta-lactam allergy).
5. Implant & Specialty Equipment Verification: Confirmation that correct generator models, lead types, active-fixation leads, introducer sheaths, and transseptal equipment are present in the room with packaging seals intact.
6. Fire Risk Score & Mitigation: A formal surgical fire risk score must be calculated and verbalized based on the surgical fire triangle:
   • Ignition Source: Electrocautery pencil, RF ablation catheter, or external defibrillator pads.
   • Fuel Source: Alcohol-based skin preps, surgical drapes, and sponges.
   • Oxidizer: Supplemental oxygen delivery.
   • Assessment: If the procedure involves an open oxygen source (nasal cannula or simple mask with FiO2 > 30%) and an active ignition source above the xiphoid, the case is scored as High Fire Risk. Protocol mandates: verify alcohol prep is 100% dry (≥ 3 minutes elapsed), lower oxygen delivery to the lowest clinically tolerated concentration (< 30% FiO2), scavenge trapped oxygen under drapes using continuous suction, and keep cautery pencils in an insulated holster.
7. Emergency Readiness & Resuscitation Plan: Confirmation that external defibrillator pads are connected with clear ECG trace visible, blood bank crossmatch status is verified, pericardiocentesis tray is immediately accessible, and reversal agents (protamine, lipid emulsion) are present.